title: [Eye Disorders Associated with S-1 Chemotherapy in Gastric Cancer Patients].
abstract: Eye disorders are one of the characteristic adverse events associated with S-1 chemotherapy. In this retrospective study, we investigated the frequency and outcome of eye disorders associated with S-1 chemotherapy in gastric cancer patients. This retrospective study included 75 advanced gastric cancer patients who received S-1 monotherapy between January 2014 and December 2015. We retrospectively evaluated the frequency, Grade, and treatment of eye disorders. Eye disorders were observed in 16 patients(21%). The median time of onset was 3(range, 1-8)months. Grade 2 watering eyes, eye discharge, and conjunctivitis were reported in 14, 8, and 4 patients, respectively. Artificial tears, fluorometholone eye-drops, and both of these treatments were used in 7, 1, and 8 patients, respectively. Ophthalmologic examination was performed for 3 patients. No delay or reduction of S-1 therapy was required for the eye disorders. Eye disorders associated with S-1 therapy in gastric cancer patients did not affect treatment if managed properly using eye drops.
authors.affiliation: Dept. of Pharmacy, Sakai City Medical Center.
authors.forename: Chika
authors.initials: C
authors.lastname: Fujii
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Makari
authors.forename: Jota
authors.initials: J
authors.lastname: Mikami
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Shunji
authors.initials: S
authors.lastname: Kamigaki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hayashi
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yanagishita
authors.forename: Yukako
authors.initials: Y
authors.lastname: Yasui
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ishizaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000601:surgery; D005641:Tegafur / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid